Authors: Verhaar Nicole, Kopp Veronika, Pfarrer Christiane, Neudeck Stephan, König Kathrin, Rohn Karl, Kästner Sabine
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary Dexmedetomidine has demonstrated promise in protecting intestinal tissue from ischaemia-reperfusion injury in equine models, yet the precise mechanisms underpinning this protective effect remain incompletely understood. Verhaar and colleagues conducted a randomised controlled trial in 12 horses to clarify whether the alpha2 adrenoreceptor pathway was essential to dexmedetomidine's protective action, comparing animals receiving dexmedetomidine alone (Dex group) against those receiving dexmedetomidine plus vatinoxan, a peripheral alpha2 antagonist (DexV group). Following 90 minutes of surgical jejunal ischaemia and 30 minutes of reperfusion, mucosal damage was quantified using injury scoring and immunohistochemical markers of cell death (cleaved caspase-3 and TUNEL staining). Notably, whilst no difference in mucosal injury emerged during the ischaemic phase itself, the DexV group exhibited significantly lower mucosal injury scores after reperfusion compared to the Dex group, with apoptotic cell counts remaining equivalent between groups. These findings suggest that peripheral alpha2 blockade does not impair dexmedetomidine's tissue-protective properties, implying that central alpha2 mechanisms—rather than peripheral receptor activity—likely mediate the drug's beneficial effects against intestinal ischaemia-reperfusion injury; this distinction may inform future clinical protocols and drug selection strategies for horses at risk of intestinal compromise.
Read the full abstract on PubMed
Practical Takeaways
- •Dexmedetomidine preconditioning may be a useful pharmacological strategy before colic surgery to reduce intestinal damage from ischaemia-reperfusion
- •Peripheral alpha2 receptor antagonism does not interfere with dexmedetomidine's protective effects, providing flexibility in anaesthetic protocols
- •Further clinical trials are needed to determine optimal dosing and timing of dexmedetomidine preconditioning in equine surgical patients
Key Findings
- •Dexmedetomidine preconditioning reduces intestinal ischaemia-reperfusion injury in horses
- •Addition of peripheral alpha2 antagonist vatinoxan did not impair dexmedetomidine's protective effect
- •Group DexV showed significantly lower mucosal injury scores after reperfusion compared to group Dex alone
- •Apoptotic cell counts measured by cleaved caspase-3 and TUNEL did not differ between treatment groups